Modifications in Mutational Landscape in Patients with Lower Risk MDS without 5Q Deletion Receiving Azacitidine Are Correlated with Clinical Response. (April 2017) - Sanchez-Garcia, J.; Hernandez-Sanchez, J.M.; Falantes, J.; Benito, R.; Medina, A.; Lumbreras, E.; Hernandez-Mohedo, F.; Hermosin, L.; Bailen, A.; Maria, S.; Casaño, J.; Calderon, C.; et al.